- Previous Close
29.550 - Open
29.600 - Bid 29.950 x --
- Ask 30.150 x --
- Day's Range
28.850 - 30.350 - 52 Week Range
14.800 - 36.850 - Volume
1,047,675 - Avg. Volume
1,736,021 - Market Cap (intraday)
11.32B - Beta (5Y Monthly) 0.49
- PE Ratio (TTM)
-- - EPS (TTM)
-3.740 - Earnings Date Mar 26, 2025 - Mar 31, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date Jul 13, 2022
- 1y Target Est
29.13
CanSino Biologics Inc. develops, manufactures, and commercializes vaccines in the People's Republic of China. The company develops Convidecia and the Ad5-nCoV for Inhalation vaccines to recombinant novel coronavirus disease; Ad5-EBOV, an Ebola virus vaccine; and MCV2 and MCV4 vaccines for the prevention of N. meningitides. It develops DTcP vaccine for infants and DTcP Booster vaccine, which are in Phase I clinical trial for addressing the weaker protection preventing pertussis after primary vaccination. In addition, it develops Tdcp Adolescent and Adult vaccine for treating pertussis; PBPV, a serotype-independent protein-based pneumococcal vaccine that is in Phase I clinical trial; PCV13i, a pneumococcal conjugate vaccine, which is in Phase I clinical trial; and TB Booster for the BCG-vaccinated population which is in Phase I clinical trial. Further, it is developing various preclinical stage products, including DTcP-Hib Combo vaccine; CS-2023 to treat meningitis; CS-2028 for treating multivalent conjugate vaccine; CS-2032 for hingles; CS-2036 to treat polio; CS-2047 for treating tetanus; and CS-2201 DTcP for combination vaccine. The company was incorporated in 2009 and is headquartered in Tianjin, the People's Republic of China.
www.cansinotech.com1,494
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: 6185.HK
View MorePerformance Overview: 6185.HK
Trailing total returns as of 12/27/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 6185.HK
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 6185.HK
View MoreValuation Measures
Market Cap
11.32B
Enterprise Value
9.90B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
11.48
Price/Book (mrq)
1.38
Enterprise Value/Revenue
15.27
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-96.20%
Return on Assets (ttm)
-7.92%
Return on Equity (ttm)
-13.62%
Revenue (ttm)
748.53M
Net Income Avi to Common (ttm)
-720.11M
Diluted EPS (ttm)
-3.740
Balance Sheet and Cash Flow
Total Cash (mrq)
3.28B
Total Debt/Equity (mrq)
41.52%
Levered Free Cash Flow (ttm)
-1.19B